Vitamin E: Potential to reduce common complications associated with venous access devices in cancer patients

Cynthia C Chernecky, Denise Macklin, Katherine Nugent, Jennifer L Waller

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Vitamin E is known to have antiplatelet, fibrinolytic, and endotoxin properties. Focus-group discussion with cancer patients who had a venous access device (VAD) revealed that 14 percent felt taking vitamin E (400-800 IU/d orally) eliminated the problems of occlusion and inability to withdraw blood from their current VADs. This information is significant in that two of the patients had these problems with their previous VADs but not with their current VADs, although they were the same type of device. These findings suggest that use of vitamin E to reduce occlusion and inability to withdraw blood in cancer patients with VADs should be investigated further.

Original languageEnglish (US)
Pages (from-to)38-40
Number of pages3
JournalJournal of Cancer Integrative Medicine
Volume3
Issue number1
StatePublished - Dec 1 2005

Fingerprint

Vitamin E
Equipment and Supplies
Neoplasms
Focus Groups
Endotoxins

Keywords

  • Complementary medicine
  • Neoplasm
  • Nursing
  • Venous access device
  • Vitamin E

ASJC Scopus subject areas

  • Oncology
  • Complementary and alternative medicine
  • Pharmacology (medical)

Cite this

Vitamin E : Potential to reduce common complications associated with venous access devices in cancer patients. / Chernecky, Cynthia C; Macklin, Denise; Nugent, Katherine; Waller, Jennifer L.

In: Journal of Cancer Integrative Medicine, Vol. 3, No. 1, 01.12.2005, p. 38-40.

Research output: Contribution to journalArticle

@article{e9821672d51b435884260d51cc3c7253,
title = "Vitamin E: Potential to reduce common complications associated with venous access devices in cancer patients",
abstract = "Vitamin E is known to have antiplatelet, fibrinolytic, and endotoxin properties. Focus-group discussion with cancer patients who had a venous access device (VAD) revealed that 14 percent felt taking vitamin E (400-800 IU/d orally) eliminated the problems of occlusion and inability to withdraw blood from their current VADs. This information is significant in that two of the patients had these problems with their previous VADs but not with their current VADs, although they were the same type of device. These findings suggest that use of vitamin E to reduce occlusion and inability to withdraw blood in cancer patients with VADs should be investigated further.",
keywords = "Complementary medicine, Neoplasm, Nursing, Venous access device, Vitamin E",
author = "Chernecky, {Cynthia C} and Denise Macklin and Katherine Nugent and Waller, {Jennifer L}",
year = "2005",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "38--40",
journal = "Journal of Cancer Integrative Medicine",
issn = "1544-6301",
publisher = "Prime National Publishing Corp.",
number = "1",

}

TY - JOUR

T1 - Vitamin E

T2 - Potential to reduce common complications associated with venous access devices in cancer patients

AU - Chernecky, Cynthia C

AU - Macklin, Denise

AU - Nugent, Katherine

AU - Waller, Jennifer L

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Vitamin E is known to have antiplatelet, fibrinolytic, and endotoxin properties. Focus-group discussion with cancer patients who had a venous access device (VAD) revealed that 14 percent felt taking vitamin E (400-800 IU/d orally) eliminated the problems of occlusion and inability to withdraw blood from their current VADs. This information is significant in that two of the patients had these problems with their previous VADs but not with their current VADs, although they were the same type of device. These findings suggest that use of vitamin E to reduce occlusion and inability to withdraw blood in cancer patients with VADs should be investigated further.

AB - Vitamin E is known to have antiplatelet, fibrinolytic, and endotoxin properties. Focus-group discussion with cancer patients who had a venous access device (VAD) revealed that 14 percent felt taking vitamin E (400-800 IU/d orally) eliminated the problems of occlusion and inability to withdraw blood from their current VADs. This information is significant in that two of the patients had these problems with their previous VADs but not with their current VADs, although they were the same type of device. These findings suggest that use of vitamin E to reduce occlusion and inability to withdraw blood in cancer patients with VADs should be investigated further.

KW - Complementary medicine

KW - Neoplasm

KW - Nursing

KW - Venous access device

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=33644693031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644693031&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33644693031

VL - 3

SP - 38

EP - 40

JO - Journal of Cancer Integrative Medicine

JF - Journal of Cancer Integrative Medicine

SN - 1544-6301

IS - 1

ER -